Ligand Pharmaceuticals, Inc. (LGND)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$316.13+0.83%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LGND
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 94.5% |
| Our one-year growth estimate | diamond | 43.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 51.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
LGND — earnings miss
Dated 2026-10-29
Results of Operations and Financial Condition. On October 29, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Secti…
Why it matters: Ligand raised its 2026 adjusted EPS range to $9.50–$9.75. The result will test whether deal gains offset higher costs.
Watch forFull-year adjusted EPS is at least $9.50, the low end of the raised range.
Also watch forFull-year adjusted EPS is below $9.50.
Why it matters: XOMA added more than 120 assets, but Q3 included deal and integration costs. Lower costs and higher adjusted EPS would show progress.
Supportive ifA later report shows lower XOMA deal and integration costs than in Q3. Adjusted EPS rises from a year earlier.
Worry ifA later report shows XOMA deal and integration costs still rising, with adjusted EPS down year over year.
Why it matters: Royalty revenue rose 51% in Q3, but full-year guidance still starts at $225 million. The next report will show if growth stays strong.
Watch forFull-year 2026 royalty revenue is at least $225 million, the low end of guidance.
Also watch forFull-year 2026 royalty revenue is below $225 million.
Why it matters: The outlook can show whether royalty growth can last beyond 2026. It can also set clear goals for new deals.
Watch forThe December 8 outlook sets clear growth goals and backs them with named assets or deal plans.
Also watch forThe outlook cuts growth goals or gives no clear goals for royalty revenue or new deals.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$140 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $316 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,470 loss on $10,000 · 14.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.